{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:39:20Z","timestamp":1769578760868,"version":"3.49.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Anti-PD1 agents are widely used in the treatment of solid tumors. This has prompted the recognition of a class of immune-related adverse events (irAEs), due to the activation of autoimmune T-cells. Pembrolizumab is an anti-PD1 agent, which has been related to an increased risk of various neurological irAE (n-irAEs). Here, we present a rare case of pembrolizumab-induced neuropathy of cranial nerves.<\/jats:p><jats:p><jats:bold>Case Report:<\/jats:bold> A 72-year-old patient was diagnosed with a lung adenocarcinoma in February 2018 (EGFR\u2013, ALK\u2013, and PDL1 90%). According to the molecular profile, pembrolizumab was started. After three administrations, the patient developed facial paresis, ptosis, ophthalmoplegia, and dysphonia. As brain metastases and paraneoplastic markers were excluded, a drug-related disorder was suspected and pembrolizumab was discontinued. A nerve conduction study and electromyography excluded signs of neuropathy and myopathy at four limbs, and repetitive nerve stimulation was negative. However, altered blink reflex and nerve facial conduction were consistent with an acute neuropathy of the cranial district. Thus, the patient was treated with two cycles of intravenous immunoglobulins (IVIg), which rapidly allowed improvement of both symptoms and neurophysiological parameters. However, the patient died in October 2018 for a progression of lung tumor.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> Only 16 cases of pembrolizumab-related neuropathies have been described so far. Our case is of particular interest for the isolated involvement of cranial nerves and the prompt response to IVIg.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> N-irAEs are insidious conditions that require solid knowledge of onco-immunotherapy complications: it is mandatory not to delay any treatment that would potentially modify the course of a neurological complication.<\/jats:p>","DOI":"10.3389\/fneur.2021.669493","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T07:14:03Z","timestamp":1620717243000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature"],"prefix":"10.3389","volume":"12","author":[{"given":"Francesco","family":"Bruno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Antonietta","family":"Palmiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Franchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Pellerino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Milanesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Soffietti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Rud\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"106088","DOI":"10.1016\/j.intimp.2019.106088","article-title":"Current status and development of anti-PD-1\/PD-L1 immunotherapy for lung cancer","volume":"79","author":"Wang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"MMT30","DOI":"10.2217\/mmt-2019-0005","article-title":"Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management","volume":"6","author":"Simeone","year":"2019","journal-title":"Melanoma Manag"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/jns.12371","article-title":"Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: experience beyond the clinical trials","volume":"25","author":"Bruna","year":"2020","journal-title":"J Peripheral Nerv Syst"},{"key":"B5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/annonc\/mdw613","article-title":"Vasculitic neuropathy induced by pembrolizumab","volume":"28","author":"Aya","year":"2017","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"de","year":"2016","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/CJI.0000000000000172","article-title":"Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment","volume":"40","author":"Diamantopoulos","year":"2017","journal-title":"J Immunother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti\u2013programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1002\/mus.25672","article-title":"Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma","volume":"56","author":"Sep\u00falveda","year":"2017","journal-title":"Muscle Nerve"},{"key":"B12","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1002\/mus.25663","article-title":"Facial diplegia after pembrolizumab treatment","volume":"56","author":"Yost","year":"2017","journal-title":"Muscle Nerve"},{"key":"B13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"137","author":"Fellner","year":"2018","journal-title":"J Neuro-Oncol"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.3371","article-title":"Case reports of pembrolizumab-induced acute inflammatory demyelinating polyneuropathy","volume-title":"Cureus","author":"Manam","year":"2018"},{"key":"B15","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1002\/mus.26101","article-title":"Guillain\u2013Barr\u00e9-like syndrome during pembrolizumab treatment","volume":"58","author":"Ong","year":"2018","journal-title":"Muscle Nerve"},{"key":"B16","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume-title":"Neurology","author":"Dubey","year":"2019"},{"key":"B17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000504930","article-title":"Treatment considerations for patients with unresectable metastatic melanoma who develop pembrolizumab-induced guillain-barr\u00e9 toxicity: a case report","volume":"13","author":"Muralikrishnan","year":"2020","journal-title":"Case Rep Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/CCO.0000000000000681","article-title":"Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice","volume":"32","author":"Berzero","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"10632","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurological autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.669493\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T07:14:07Z","timestamp":1620717247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.669493\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":20,"alternative-id":["10.3389\/fneur.2021.669493"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.669493","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"article-number":"669493"}}